Jefferies Reiterates Buy Rating on Akero Therapeutics (AKRO)

May 13, 2025 2:26 PM EDT Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $75.00 price target on Akero Therapeutics (NASDAQ: AKRO).The analyst comments "AKRO ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login